title: Crohn's disease patients treated with adalimumab benefit from co-treatment with immunomodulators.
authors: Mirthe E
authors: ME
authors: van der Valk
authors: Martijn G H
authors: MG
authors: van Oijen
authors: Marije
authors: M
authors: Ammerlaan
authors: Peter D
authors: PD
authors: Siersema
authors: Bas
authors: B
authors: Oldenburg
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008297:Male
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents